FIELD: medicine.
SUBSTANCE: group of inventions concerns treatment of chronic heart failure (CHF). To this end, a preliminary test is performed to determine the plasma level of the N-terminal probrain natriuretic peptide (NT-proBNP), and at the NT-proBNP level less than or equal to 4,000 fmoles/ml, neuregulin is administered.
EFFECT: effective treatment by identification of a group of patients for whom neuregulin treatment is the most appropriate.
32 cl, 3 ex, 3 tbl
